Creutzfeldt-Jakob disease is a rare, but rapidly progressive, up to now 
untreatable and fatal neurodegenerative disorder. Clinical diagnosis of 
Creutzfeldt-Jakob disease (CJD) is difficult; however, it can be facilitated by 
suitable biomarkers. Aim of the present study is to compare levels of 
cerebrospinal fluid biomarkers (total tau protein, phosphorylated-tau protein, 
protein 14-3-3 and amyloid beta) in Slovak population of CJD suspect cases, 
retrospectively in over a 10-year period. One thousand three hundred sixty-four 
CSF samples from patients with suspect CJD, forming a homogenous group in terms 
of geographical as well as of equal transport conditions, storage and laboratory 
processing, were analysed. Definite diagnosis of Creutzfeldt-Jakob disease was 
confirmed in 101 patients with genetic form, and 60 patients with its sporadic 
form of the disease. Specificity of protein 14-3-3 and total tau in both forms 
CJD was similar (87 % for P14-3-3/85 % for total tau), sensitivity to P 14-3-3 
and total tau was higher in sporadic Creutzfeldt-Jakob disease (sCJD) (90/95 %) 
than in genetic Creutzfeldt-Jakob disease (gCJD) (89/74 %). As expected, the 
total tau levels were significantly higher in CJD patients than in controls, but 
there was also significant difference between gCJD and sCJD (levels in gCJD were 
lower; p = 0.003). There was no significant difference in p-tau and Aβ 1-42 
levels neither between both CJD forms nor between CJD patients and control 
group.